Skip to main content
SpringerLink
Log in

Influenza Vaccination and Antiviral Therapy

Is There a Role for Concurrent Administration in the Institutionalised Elderly?

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Influenza vaccination is estimated to be 50–68% efficacious in preventing pneumonia, hospitalisation or death in nursing home residents. Large culture-proven outbreaks may occur despite high resident vaccination rates. There is, therefore, a significant role for concurrent administration of influenza vaccination and antiviral therapy. The use of antiviral treatment and chemoprophylaxis requires community reporting of viral isolates, and contingency plans for rapid case identification and application of antiviral therapy. Clinicians must react quickly to control a highly infectious seasonal pathogen that may strike as an explosive outbreak. This situation is unique in geriatric practice. Current antiviral treatment should be administered within 48 hours of symptom onset, and is more efficacious if administered within 12 hours. In the case of an explosive institutional outbreak, a 1-day delay in prophylaxis may allow infection of many residents with a potentially fatal illness. Influenza must be differentiated from other respiratory viruses or syndromes. Grouped rapid diagnostic tests can aid laboratory confirmation.

Antiviral agents include the M2 inhibitors, amantadine and rimantadine, active against influenza A, and the neuraminidase inhibitors, zanamivir and oseltamivir, active against influenza A and B. In our experience, influenza B illness is as severe as influenza A. All agents have similar efficacy as treatment and prophylaxis against sensitive strains. When M2 inhibitors are used simultaneously within an enclosed space (i.e. household or nursing home) as both treatment and prophylaxis, resistant strains may emerge that limit prophylactic efficacy. When M2 inhibitors are administered to suspected cases (residents or staff) in institutions, precautions against secretion are especially important to diminish the risk of transmission of resistant virus.

Rimantadine has been shown to have significantly fewer CNS adverse events compared with amantadine. Amantadine and oseltamivir require dosage adjustment in those with renal impairment. Oseltamivir, rimantadine and amantadine are administered by mouth, while zanamivir is administered by oral inhalation in a lactose powder. The labelling advises caution in the use of zanamivir in those with underlying airway disease. Pooled analysis of studies in patients given zanamivir indicate that individuals over the age of 50 years (at high risk for complications) and those severely symptomatic at presentation, tend to benefit most from early treatment. Neuraminidase inhibitors also diminish the need for antibacterials to treat secondary complications.

An institutional programme to control influenza should include vaccination, and contingency plans for clinical surveillance, specimen processing and the rapid application of antiviral treatment and prophylaxis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Drinka PJ, Gravenstein S, Krause P, et al. Outbreaks of influenza A and B in a highly immunized nursing home population. J Fam Pract 1997; 45: 509–14

    PubMed  CAS  Google Scholar 

  2. Drinka PJ, Langer L, Krause P, et al. Mortality following isolation of various respiratory viruses in nursing home residents. Infect Control Hosp Epidemiol 1999; 20: 812–5

    Article  PubMed  CAS  Google Scholar 

  3. Drinka PJ, Krause P, Nest L, et al. The effect of culture-positive influenza type A on resource utilization and adverse events in nursing home residents. J Am Geriatr Soc 2002; 50: 1416–20

    Article  PubMed  Google Scholar 

  4. Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the ACIP. MMWR Morb Mortal Wkly Rep 2001; 50(RR04): 1–46

    Google Scholar 

  5. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518–27

    PubMed  CAS  Google Scholar 

  6. Postma MJ, Baltussen RMPM, Heijnen MLA, et al. Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging 2000; 17: 217–27

    Article  PubMed  CAS  Google Scholar 

  7. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. JAMA 1994; 272: 1661–5

    Article  PubMed  CAS  Google Scholar 

  8. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281: 908–13

    Article  PubMed  CAS  Google Scholar 

  9. Drinka PJ, Krause P, Nest L, et al. Experience with the Rapid Directigen™; test for influenza [letter]. Infect Control Hosp Epidemiol 2002; 23: 561

    Article  PubMed  Google Scholar 

  10. Drinka P, Gravenstein S, Krause P, et al. Non-Influenza respiratory viruses may overlap and obscure influenza activity. J Am Geriatr Soc 1999; 47: 1087–93

    PubMed  CAS  Google Scholar 

  11. Cox NJ, Fukuda K. Influenza. Infect Dis Clin North Am 1998; 12: 27–38

    Article  PubMed  CAS  Google Scholar 

  12. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54

    Article  PubMed  CAS  Google Scholar 

  13. Bradley SE, LTC Committee of the Society for Healthcare Epidemiology of America. Prevention of influenza in long-term care facilities. Infect Control Hosp Epidemiol 1999; 20: 629–37

    Article  PubMed  CAS  Google Scholar 

  14. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827–35

    Article  PubMed  CAS  Google Scholar 

  15. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343: 1282–9

    Article  PubMed  CAS  Google Scholar 

  16. Gravenstein S, Drinka PJ, Osterweil D, et al. A multicenter prospective double-blind randomized controlled trial comparing the relative safety and efficacy of zanamivir to rimantadine for nursing home influenza outbreak control [abstract]. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto (ON), 1155

  17. Gomolin IH, Leib HB, Arden NH, et al. Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management. J Am Geriatr Soc 1995; 43: 71–4

    PubMed  CAS  Google Scholar 

  18. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43

    Article  PubMed  CAS  Google Scholar 

  19. Peters P, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49: 1025–31

    Article  PubMed  Google Scholar 

  20. Drinka PJ, Krause P, Nest L, et al. Delays in the application of outbreak control prophylaxis for influenza A in a nursing home. Infect Control Hosp Epidemiol 2002; 23: 600–3

    Article  PubMed  Google Scholar 

  21. Patriarca PA, Arden NH, Koplan JP, et al. Prevention and control of type A influenza infections in nursing homes. Ann Intern Med 1987; 107: 732–40

    PubMed  CAS  Google Scholar 

  22. McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs 2001; 61: 263–83

    Article  PubMed  CAS  Google Scholar 

  23. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254–61

    Article  PubMed  CAS  Google Scholar 

  24. Kandel R, Hartshorn KL. Prophylaxis and treatment of influenza virus infection. BioDrugs 2001; 15: 303–23

    Article  PubMed  CAS  Google Scholar 

  25. Jefferson T, Demicheli V, Rivetti D, et al. Cochrane reviews and systematic reviews of economic evaluations: Amantadine and rimantadine in the prevention and treatment of influenza. Pharmacoeconomics 1999; 16Suppl. 1: 85–9

    Article  PubMed  Google Scholar 

  26. Dolan R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580–4

    Article  Google Scholar 

  27. Symmetrel® (amantiadine hydrochloride). In: Physicians’ Desk Reference®. 56th ed. Montvale (NJ): Medical Economics Company, Inc., 2002: 1328–30

  28. Keyser L, Karl M, Nafziger A, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000; 160: 1485–8

    Article  PubMed  CAS  Google Scholar 

  29. Cohen HE, editor. Rx Products [chapter 9]. In: 2002 Drug Topics® Red Book®. Montvale (NJ): Thomsen Medical Economics, 2002

  30. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161: 212–7

    Article  PubMed  CAS  Google Scholar 

  31. Fleming DM, Moult AB, Keene O. Indicators and significance of severity in influenza patients. International Congress Series 2001; 1219: 637–43

    Article  Google Scholar 

  32. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy analysis. J Antimicrob Chemother 1999; 44: 23–9

    Article  PubMed  CAS  Google Scholar 

  33. Relenza™ (zanamivir) [prescribing information]. Research Triangle Park (NC): Glaxo Wellcome, Inc., 2000

  34. Murphy KR, Eivindson A, Pauksens K, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multi-centre study. Clin Drug Invest 2000; 20: 337–49

    Article  CAS  Google Scholar 

  35. Zaug M, Mahoney P, Ward P, et al. Oral oseltamivir is effective in the treatment of acute influenza in a vaccinated population. Clinical Microbiol Infect 2000; 6Suppl. 1: 139

    Google Scholar 

  36. Nicholson KG, Aoki FY, Osterhaus ADME, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 2000; 355: 1845–50

    Article  PubMed  CAS  Google Scholar 

  37. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000; 21: 700–4

    Article  PubMed  CAS  Google Scholar 

  38. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of Rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321: 1696–702

    Article  PubMed  CAS  Google Scholar 

  39. Jackson HC, Roberts N, Wang ZM, et al. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Invest 2000; 20: 447–54

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The author has been a speaker for Roche and Glaxo, and has received research funding from Glaxo. The author received no funding to assist with the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Internal Medicine, Geriatrics, University of Wisconsin, Madison, Wisconsin, USA

    Paul J. Drinka

Authors
  1. Paul J. Drinka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul J. Drinka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drinka, P.J. Influenza Vaccination and Antiviral Therapy. Drugs Aging 20, 165–174 (2003). https://doi.org/10.2165/00002512-200320030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320030-00001

Keywords

Search

Navigation